Anaergia (ANRG) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
12 Nov, 2026Executive summary
Q3 revenue rose 30.3% YoY to C$66.9 million; nine-month revenue rose 71.5% to C$186.0 million, exceeding FY2025 revenue of C$180.2 million.
Revenue Backlog reached a record C$303.1 million at September 30, with a 1.48 book-to-bill ratio; Adjusted EBITDA was positive for a fifth consecutive quarter.
Rhode Island and Charlotte asset sales generated a C$21.9 million gain, removed US$20 million of project-level debt and negative earnings, and sharpened portfolio focus.
Financial highlights
Q3 revenue was C$66.9 million, up 30.3% YoY; nine-month revenue was C$186.0 million, up 71.5%.
Q3 gross profit rose 11.0% to C$16.4 million; nine-month gross profit increased 42.1% to C$43.6 million.
Q3 net income was C$19.5 million versus a C$0.5 million loss; nine-month net income was C$13.1 million versus a C$15.8 million loss, including the C$21.9 million disposal gain.
Q3 Adjusted EBITDA was C$3.1 million, up 21.7% YoY; nine-month Adjusted EBITDA was C$6.1 million versus a C$3.6 million loss.
Nine-month operating loss narrowed to C$1.9 million from C$9.2 million; Q3 operating income was C$0.5 million versus C$0.6 million.
Outlook and guidance
Management is focused on converting backlog to revenue through disciplined execution, improving operating leverage, and selectively pursuing opportunities against return and risk criteria.
Capital sales backlog is expected to be materially higher by year-end; management anticipated further award announcements in the coming weeks.
SoCal Biomethane is expected to approach full capacity over coming quarters into next year as production ramps to expanded SB 1440 offtake volumes.
Management expects divestitures to benefit future periods by removing negative earnings contributions; projected cash flows and available financing are considered sufficient for 12 months, though execution is not assured.
Live Oak covenant compliance was expected by December 31, 2026; the lender waived the September 30 breach but retained call rights.
Latest events from Anaergia
- Q3 revenue rose 30.3% YoY as backlog reached C$303.1M.ANRG
Investor presentation - Revenue up 98% year-over-year, positive adjusted EBITDA, and expanding contract backlog.ANRG
Q2 2026 - Q2 2026 revenue nearly doubled to $63.9M, with a $275M backlog and global market leadership.ANRG
Investor presentation - All proposals were approved, directors elected, and auditors re-appointed at the AGM.ANRG
AGM 2026 - Q3 2025 delivered 77% revenue growth, positive adjusted EBITDA, and a $287M backlog.ANRG
Q3 2025 - Revenue up 36.8%, gross margin at 32.5%, and backlog up 137%, supporting strong growth momentum.ANRG
Q2 2025 - Improved EBITDA, reduced losses, and strong cash position support a capital-light growth strategy.ANRG
Q3 2024 - Record $200M backlog, improved margins, and global contracts drive strong growth.ANRG
Q1 2025 - Improved margins, reduced losses, and a $103.3M backlog support strong 2025 growth.ANRG
Q4 2024